{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:29:09Z","timestamp":1762900149045,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018550","name":"The Lowy Medical Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018550","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We aimed to investigate non-exudative microcystoid macular abnormalities for visual and anatomical outcome in patients with retinal vein occlusion (RVO) with and without glaucomatous optic neuropathy (GON).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medical records of 124 eyes (105 patients) with RVO were reviewed and analyzed. Eyes demonstrating microcystoid macular abnormalities were divided into 2 groups, those with evidence of glaucoma (group A) and those without glaucoma (group B). Best-corrected visual acuity (BCVA), the prevalence and number of microcystoid macular abnormalities, and number of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections were compared at baseline and follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-one out of 105 eyes (67.6%) with RVO displayed microcystoid macular abnormalities. Thirty-eight out of 71 eyes (53.5%) presented with concomitant glaucoma (group A), while the remaining 33 eyes (42.6%) had no history of glaucoma (group B). At the end of the follow-up period, mean BCVA was worse in group A versus group B (20\/80 versus 20\/40, respectively; p\u2009=\u2009.003). The mean number of anti-VEGF injections was 10.1\u2009\u00b1\u20099.2 in group A versus 5.9\u2009\u00b1\u20096.9 in group B (p\u2009=\u2009.03).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Eyes with RVO and concomitant glaucoma exhibited a significantly higher number of microcystoid macular abnormalities and worse BCVA versus eyes with RVO without glaucoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-021-05250-9","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:31:30Z","timestamp":1624336290000},"page":"3579-3588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of non-exudative microcystoid macular abnormalities secondary to retinal vein occlusion"],"prefix":"10.1007","volume":"259","author":[{"given":"Anibal","family":"Francone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Govetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"Essilfie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouros","family":"Nouri-Mahdavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-3467","authenticated-orcid":false,"given":"Jean-Pierre","family":"Hubschman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"4","key":"5250_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10792-007-9123-0","volume":"28","author":"D Shroff","year":"2008","unstructured":"Shroff D, Mehta DK, Arora R et al (2008) Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study. Int Ophthalmol 28(4):261\u2013268","journal-title":"Int Ophthalmol"},{"issue":"6","key":"5250_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L et al (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1113-1123.e15","journal-title":"Ophthalmology"},{"issue":"8","key":"5250_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594\u20131602","journal-title":"Ophthalmology"},{"issue":"6","key":"5250_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124-1133.e1","journal-title":"Ophthalmology"},{"issue":"3","key":"5250_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429-437.e7","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5250_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"J-F Korobelnik","year":"2014","unstructured":"Korobelnik J-F, Holz FG, Roider J et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO Study. Ophthalmology 121(1):202\u2013208","journal-title":"Ophthalmology"},{"issue":"2","key":"5250_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study. Ophthalmology 123(2):330\u2013336","journal-title":"Ophthalmology"},{"issue":"10","key":"5250_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","volume":"102","author":"JG Clarkson","year":"1995","unstructured":"Clarkson JG, Chuang E, Gass D et al (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion The Central Vein Occlusion Study Group M report. Ophthalmology 102(10):1425\u201333","journal-title":"Ophthalmology"},{"key":"5250_CR9","unstructured":"Lumbroso B, Rispoli M. (2012) Practical handbook of OCT. First Edition. New Delhi. Jaypee Brothers. 145\u2013148 p."},{"issue":"2","key":"5250_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1167\/iovs.13-12912","volume":"55","author":"MC Burggraaff","year":"2014","unstructured":"Burggraaff MC, Trieu J, de Vries-Knoppert WAEJ et al (2014) The clinical spectrum of microcystic macular edema. Invest Ophthalmol Vis Sci 55(2):952\u2013961","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"5250_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1097\/IAE.0b013e31828e68d0","volume":"33","author":"B Wolff","year":"2013","unstructured":"Wolff B, Basdekidou C, Vasseur V et al (2013) Retinal inner nuclear layer microcystic changes in optic nerve atrophy: a novel spectral-domain OCT finding. Retina Phila Pa 33(10):2133\u20132138","journal-title":"Retina Phila Pa"},{"issue":"4","key":"5250_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/ICB.0000000000000197","volume":"9","author":"X Chen","year":"2015","unstructured":"Chen X, Kuehlewein L, Pineles SL et al (2015) En face optical coherence tomography of macular microcysts due to optic neuropathy from neuromyelitis optica. Retin Cases Brief Rep 9(4):302\u2013306","journal-title":"Retin Cases Brief Rep"},{"issue":"6","key":"5250_CR13","doi-asserted-by":"publisher","first-page":"e0130175","DOI":"10.1371\/journal.pone.0130175","volume":"10","author":"T Hasegawa","year":"2015","unstructured":"Hasegawa T, Akagi T, Yoshikawa M et al (2015) microcystic inner nuclear layer changes and retinal nerve fiber layer defects in eyes with glaucoma. PLoS ONE 10(6):e0130175","journal-title":"PLoS ONE"},{"issue":"3","key":"5250_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/IJG.0000000000000129","volume":"25","author":"JC Wen","year":"2016","unstructured":"Wen JC, Freedman SF, El-Dairi MA et al (2016) Microcystic macular changes in primary open-angle glaucoma. J Glaucoma 25(3):258\u2013262","journal-title":"J Glaucoma"},{"key":"5250_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2017.06.023","volume":"181","author":"A Govetto","year":"2017","unstructured":"Govetto A, Su D, Farajzadeh M et al (2017) Microcystoid macular changes in association with idiopathic epiretinal membranes in eyes with and without glaucoma: clinical insights. Am J Ophthalmol 181:156\u2013165","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5250_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ophtha.2013.08.045","volume":"121","author":"M Abegg","year":"2014","unstructured":"Abegg M, Dysli M, Wolf S et al (2014) Microcystic macular edema: retrograde maculopathy caused by optic neuropathy. Ophthalmology 121(1):142\u2013149","journal-title":"Ophthalmology"},{"issue":"2","key":"5250_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajo.2010.02.019","volume":"150","author":"SY Cohen","year":"2010","unstructured":"Cohen SY, Dubois L, Nghiem-Buffet S et al (2010) Retinal pseudocysts in age-related geographic atrophy. Am J Ophthalmol 150(2):211-217.e1","journal-title":"Am J Ophthalmol"},{"key":"5250_CR18","doi-asserted-by":"crossref","unstructured":"Balk LJ, Killestein J, Polman CH et al. (2012) Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain J Neurol. 135(Pt 12):e226; author reply e227.","DOI":"10.1093\/brain\/aws216"},{"issue":"4","key":"5250_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","volume":"112","author":"TY Wong","year":"2005","unstructured":"Wong TY, Larsen EKM, Klein R et al (2005) Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the atherosclerosis risk in communities & cardiovascular health studies. Ophthalmology 112(4):540\u2013547","journal-title":"Ophthalmology"},{"issue":"7","key":"5250_CR20","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jth.12982","volume":"13","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Elbaz H, Peto T et al (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost JTH 13(7):1254\u20131263","journal-title":"J Thromb Haemost JTH"},{"issue":"4","key":"5250_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archopht.126.4.513","volume":"126","author":"R Klein","year":"1960","unstructured":"Klein R, Moss SE, Meuer SM et al (1960) (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol Chic Ill 126(4):513\u2013518","journal-title":"Arch Ophthalmol Chic Ill"},{"key":"5250_CR22","unstructured":"Schachat AP, Wilkinson CP, Hinton DR et al. (2018) Ryan\u2019s RETINA. Sixth Edition. Vol. II. Elsevier. 1157 p."},{"key":"5250_CR23","unstructured":"Hodapp E, Parrish RK II, Anderson DR. (1993) Clinical decisions in glaucoma. St Louis: The CV: Mosby Co. 52\u201361 p."},{"key":"5250_CR24","doi-asserted-by":"crossref","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol Chic Ill 1960. 103(12):1796\u2013806.","DOI":"10.1001\/archopht.1985.01050120030015"},{"issue":"2","key":"5250_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2014-305737","volume":"100","author":"JW Pott","year":"2016","unstructured":"Pott JW, de Vries-Knoppert WA, Petzold A (2016) The prevalence of microcystic macular changes on optical coherence tomography of the macular region in optic nerve atrophy of non-neuritis origin: a prospective study. Br J Ophthalmol 100(2):216\u2013221","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"5250_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/bjo.60.6.411","volume":"60","author":"L Laatikainen","year":"1976","unstructured":"Laatikainen L, Kohner EM (1976) Fluorescein angiography and its prognostic significance in central retinal vein occlusion. Br J Ophthalmol 60(6):411\u2013418","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"5250_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","volume":"25","author":"A Bringmann","year":"2006","unstructured":"Bringmann A, Pannicke T, Grosche J et al (2006) M\u00fcller cells in the healthy and diseased retina. Prog Retin Eye Res 25(4):397\u2013424","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"5250_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaneurol.2013.1832","volume":"70","author":"JM Gelfand","year":"2013","unstructured":"Gelfand JM, Cree BA, Nolan R et al (2013) Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol 70(5):629\u2013633","journal-title":"JAMA Neurol"},{"issue":"5","key":"5250_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00417-006-0516-y","volume":"245","author":"A Reichenbach","year":"2007","unstructured":"Reichenbach A, Wurm A, Pannicke T et al (2007) M\u00fcller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 245(5):627\u2013636","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"4","key":"5250_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.mcn.2004.04.005","volume":"26","author":"T Pannicke","year":"2004","unstructured":"Pannicke T, Iandiev I, Uckermann O et al (2004) A potassium channel-linked mechanism of glial cell swelling in the postischemic retina. Mol Cell Neurosci 26(4):493\u2013502","journal-title":"Mol Cell Neurosci"},{"issue":"1\u20132","key":"5250_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jneuroim.2005.01.003","volume":"161","author":"T Pannicke","year":"2005","unstructured":"Pannicke T, Uckermann O, Iandiev I et al (2005) Ocular inflammation alters swelling and membrane characteristics of rat M\u00fcller glial cells. J Neuroimmunol 161(1\u20132):145\u2013154","journal-title":"J Neuroimmunol"},{"issue":"10","key":"5250_CR32","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/IAE.0000000000001158","volume":"36","author":"RF Spaide","year":"2016","unstructured":"Spaide RF (2016) Retinal vascular cystoid macular edema: review and new theory. Retina Phila Pa 36(10):1823\u20131842","journal-title":"Retina Phila Pa"},{"issue":"5","key":"5250_CR33","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1167\/iovs.08-2332","volume":"50","author":"M Rehak","year":"2009","unstructured":"Rehak M, Hollborn M, Iandiev I et al (2009) Retinal gene expression and M\u00fcller cell responses after branch retinal vein occlusion in the rat. Invest Ophthalmol Vis Sci 50(5):2359\u20132367","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"5250_CR34","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1167\/iovs.07-0980","volume":"49","author":"SS Choi","year":"2008","unstructured":"Choi SS, Zawadzki RJ, Keltner JL et al (2008) Changes in cellular structures revealed by ultra-high resolution retinal imaging in optic neuropathies. Invest Ophthalmol Vis Sci 49(5):2103\u20132119","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5250_CR35","doi-asserted-by":"crossref","unstructured":"Sebag J. (2014) Vitreous in health and disease. Springer. 407\u2013420 p.","DOI":"10.1007\/978-1-4939-1086-1"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05250-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T09:17:27Z","timestamp":1636708647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05250-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5250"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05250-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"15 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of the University of California Los Angeles, CA, USA and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.Informed consent.Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Kouros Nouri-Mahdavi has received unrestricted grant, hardware, and software support from Heidelberg Engineering (Germany). David Sarraf is a consultant for Amgen (Thousand Oaks, California, USA), Bayer (Leverkusen, Germany), Genentech (San Francisco, California, USA), Novartis (Basel, Switzerland), and Optovue (Fremont, California, USA) and receives research support from Genentech (San Francisco, California, USA), Heidelberg Engineering (Germany), Optovue (Fremont, California, USA) and Regeneron Pharmaceuticals, Inc. Jean Pierre Hubschman is a consultant for Alcon (Fort Worth, TX, USA) and Allergan (Parsippany-Troy Hills, NJ, USA), and receives research support from The Lowy\u00a0Medical Research\u00a0Institute (La Jolla, CA, USA). Anibal Francone, Andrea Govetto, Lisa Yun, and Juliet Essilfie certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}